Thrombophilic screening in Turner syndrome

V. Calcaterra, G. Gamba, N. Montani, A. De Silvestri, V. Terulla, G. Lanati, D. Larizza

Research output: Contribution to journalArticle

Abstract

Aim: The aim of this study was to determine, in patients with Turner syndrome (TS), the prevalence of thrombophilic disorders correlating with a higher risk of venous thromboembolism (VTE), to evaluate if thrombophilia is associated with the genetic features of these patients and whether screening before hormone replacement therapy (HRT) is advisable. Patients and methods: We examined 82 TS patients. In all patients we analyzed activated factor VIII:C, fibrinogen, antithrombin (AT), protein C (PC), protein S (PS), activated PC resistance, and homocysteine. For every patient, an investigation for mutations in prothrombin G20210A, factor V R506Q, methylenetetrahydropholate reductase (MTHFR) C 677T and A1298C was conducted. Results: Low values of PC in 3 patients (3.70%), low values of PS in 12 (14.81%), and hyperhomocysteinemia in 4 (4.87%) were found; 52 girls (64.2%) presented hyperfibrinogenemia. Three patients were heterozygous for the prothrombin G20210A allele mutation (3.66%) and the factor V mutation was present in 4 patients (4.88%). No TS patient had a homozygous mutation. Mutations in the MTHFR gene were present in 62 girls, in 17 patients (20.7%) they were homozygous and in 45 patients (54.88%) heterozygous. Conclusions: Considering the increased risks with the association between VTE and the higher prevalence of PC and PS deficiencies, TT genotype mutations and high level of fibrinogen, it is advisable to perform a complete thrombophilia screening in TS patients before starting HRT.

Original languageEnglish
Pages (from-to)676-679
Number of pages4
JournalJournal of Endocrinological Investigation
Volume34
Issue number9
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Turner Syndrome
Mutation
Protein C
Thrombophilia
Factor V
Protein S
Venous Thromboembolism
Hormone Replacement Therapy
Prothrombin
Fibrinogen
Factor VIIIa
Antithrombin Proteins
Protein S Deficiency
Activated Protein C Resistance
Hyperhomocysteinemia
Homocysteine
Oxidoreductases

Keywords

  • Hormone replacement therapy
  • Screening
  • Thrombophilia
  • Turner syndrome
  • Venous thromboembolism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Thrombophilic screening in Turner syndrome. / Calcaterra, V.; Gamba, G.; Montani, N.; De Silvestri, A.; Terulla, V.; Lanati, G.; Larizza, D.

In: Journal of Endocrinological Investigation, Vol. 34, No. 9, 10.2011, p. 676-679.

Research output: Contribution to journalArticle

Calcaterra, V. ; Gamba, G. ; Montani, N. ; De Silvestri, A. ; Terulla, V. ; Lanati, G. ; Larizza, D. / Thrombophilic screening in Turner syndrome. In: Journal of Endocrinological Investigation. 2011 ; Vol. 34, No. 9. pp. 676-679.
@article{21b110b85c14496eb8daa1b89c12dd86,
title = "Thrombophilic screening in Turner syndrome",
abstract = "Aim: The aim of this study was to determine, in patients with Turner syndrome (TS), the prevalence of thrombophilic disorders correlating with a higher risk of venous thromboembolism (VTE), to evaluate if thrombophilia is associated with the genetic features of these patients and whether screening before hormone replacement therapy (HRT) is advisable. Patients and methods: We examined 82 TS patients. In all patients we analyzed activated factor VIII:C, fibrinogen, antithrombin (AT), protein C (PC), protein S (PS), activated PC resistance, and homocysteine. For every patient, an investigation for mutations in prothrombin G20210A, factor V R506Q, methylenetetrahydropholate reductase (MTHFR) C 677T and A1298C was conducted. Results: Low values of PC in 3 patients (3.70{\%}), low values of PS in 12 (14.81{\%}), and hyperhomocysteinemia in 4 (4.87{\%}) were found; 52 girls (64.2{\%}) presented hyperfibrinogenemia. Three patients were heterozygous for the prothrombin G20210A allele mutation (3.66{\%}) and the factor V mutation was present in 4 patients (4.88{\%}). No TS patient had a homozygous mutation. Mutations in the MTHFR gene were present in 62 girls, in 17 patients (20.7{\%}) they were homozygous and in 45 patients (54.88{\%}) heterozygous. Conclusions: Considering the increased risks with the association between VTE and the higher prevalence of PC and PS deficiencies, TT genotype mutations and high level of fibrinogen, it is advisable to perform a complete thrombophilia screening in TS patients before starting HRT.",
keywords = "Hormone replacement therapy, Screening, Thrombophilia, Turner syndrome, Venous thromboembolism",
author = "V. Calcaterra and G. Gamba and N. Montani and {De Silvestri}, A. and V. Terulla and G. Lanati and D. Larizza",
year = "2011",
month = "10",
doi = "10.3275/7724",
language = "English",
volume = "34",
pages = "676--679",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "9",

}

TY - JOUR

T1 - Thrombophilic screening in Turner syndrome

AU - Calcaterra, V.

AU - Gamba, G.

AU - Montani, N.

AU - De Silvestri, A.

AU - Terulla, V.

AU - Lanati, G.

AU - Larizza, D.

PY - 2011/10

Y1 - 2011/10

N2 - Aim: The aim of this study was to determine, in patients with Turner syndrome (TS), the prevalence of thrombophilic disorders correlating with a higher risk of venous thromboembolism (VTE), to evaluate if thrombophilia is associated with the genetic features of these patients and whether screening before hormone replacement therapy (HRT) is advisable. Patients and methods: We examined 82 TS patients. In all patients we analyzed activated factor VIII:C, fibrinogen, antithrombin (AT), protein C (PC), protein S (PS), activated PC resistance, and homocysteine. For every patient, an investigation for mutations in prothrombin G20210A, factor V R506Q, methylenetetrahydropholate reductase (MTHFR) C 677T and A1298C was conducted. Results: Low values of PC in 3 patients (3.70%), low values of PS in 12 (14.81%), and hyperhomocysteinemia in 4 (4.87%) were found; 52 girls (64.2%) presented hyperfibrinogenemia. Three patients were heterozygous for the prothrombin G20210A allele mutation (3.66%) and the factor V mutation was present in 4 patients (4.88%). No TS patient had a homozygous mutation. Mutations in the MTHFR gene were present in 62 girls, in 17 patients (20.7%) they were homozygous and in 45 patients (54.88%) heterozygous. Conclusions: Considering the increased risks with the association between VTE and the higher prevalence of PC and PS deficiencies, TT genotype mutations and high level of fibrinogen, it is advisable to perform a complete thrombophilia screening in TS patients before starting HRT.

AB - Aim: The aim of this study was to determine, in patients with Turner syndrome (TS), the prevalence of thrombophilic disorders correlating with a higher risk of venous thromboembolism (VTE), to evaluate if thrombophilia is associated with the genetic features of these patients and whether screening before hormone replacement therapy (HRT) is advisable. Patients and methods: We examined 82 TS patients. In all patients we analyzed activated factor VIII:C, fibrinogen, antithrombin (AT), protein C (PC), protein S (PS), activated PC resistance, and homocysteine. For every patient, an investigation for mutations in prothrombin G20210A, factor V R506Q, methylenetetrahydropholate reductase (MTHFR) C 677T and A1298C was conducted. Results: Low values of PC in 3 patients (3.70%), low values of PS in 12 (14.81%), and hyperhomocysteinemia in 4 (4.87%) were found; 52 girls (64.2%) presented hyperfibrinogenemia. Three patients were heterozygous for the prothrombin G20210A allele mutation (3.66%) and the factor V mutation was present in 4 patients (4.88%). No TS patient had a homozygous mutation. Mutations in the MTHFR gene were present in 62 girls, in 17 patients (20.7%) they were homozygous and in 45 patients (54.88%) heterozygous. Conclusions: Considering the increased risks with the association between VTE and the higher prevalence of PC and PS deficiencies, TT genotype mutations and high level of fibrinogen, it is advisable to perform a complete thrombophilia screening in TS patients before starting HRT.

KW - Hormone replacement therapy

KW - Screening

KW - Thrombophilia

KW - Turner syndrome

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84856161084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856161084&partnerID=8YFLogxK

U2 - 10.3275/7724

DO - 10.3275/7724

M3 - Article

C2 - 21586893

AN - SCOPUS:84856161084

VL - 34

SP - 676

EP - 679

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 9

ER -